title: [Clinical observation on treatment of IgA nephropathy with Huobahuagen Tablets and irbesartan].
abstract: OBJECTIVE
  To observe the effects of Huobahuagen Tablets combined with irbesartan on the risk factors of IgA nephropathy.
  
  
  METHODS
  Sixty-two patients diagnosed as IgA nephropathy were randomly divided into control group and treatment group. Thirty patients in the control group were treated with Huobahuagen Tablets (5 tablets po t.i.d.), and 32 patients in the treatment group were treated with irbesartan (150 to 300 mg po q.d.), besides the same treatment as the control group. After 3 months of treatment, the levels of blood pressure (BP), 24 h urine protein (Upr), urinary red blood cells (URBC), blood triglycerides (TG), total cholesterol (TC), albumin (Alb), alanine transaminase (ALT), white blood cells (WBC) and serum creatinine (Scr) were observed.
  
  
  RESULTS
  After treatment, the levels of Upr, URBC and Scr in both groups were decreased, as compared with those before treatment (P<0.05 or P<0.01), and the levels of BP, Upr, URBC and Scr in the treatment group were lower than those in the control group (P<0.01). The levels of Alb in both groups were increased, as compared with those before treatment (P<0.05 or P<0.01), and the level of Alb in the treatment group was higher than that in the control group (P<0.05).
  
  
  CONCLUSIONS
  Huobahuagen Tablets, when used together with irbesartan, may improve the renal function of the patients with IgA nephropathy and slow the deterioration of the disease by reducing BP, Upr, URBC and Scr.
authors.affiliation: Department of Nephrology, Donghua Hospital, Sun Yat-sen University, Dongguan, Guangdong Province 523010, China. gxd-333@163.com
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Guan
authors.forename: Yu-Fang
authors.initials: YF
authors.lastname: Wu
authors.forename: Wen
authors.initials: W
authors.lastname: Zhao
mesh_terms: D000293:Adolescent; D000328:Adult; D000804:Angiotensin II / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use; D005260:Female; D005922:Glomerulonephritis, IGA / Q000188:drug therapy*; D006801:Humans; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D013607:Tablets; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001713:Biphenyl Compounds; D004365:Drugs, Chinese Herbal; D013607:Tablets; D013777:Tetrazoles; D000804:Angiotensin II; D000077405:Irbesartan